Stephens & Co. Reiterates Overweight on C4 Therapeutics, Maintains $6 Price Target
Benzinga Newsdesk 1 year ago
NewsPrice TargetReiterationAnalyst Ratings
Stephens & Co. analyst Sudan Loganathan reiterates C4 Therapeutics (NASDAQ:CCCC) with a Overweight and maintains $6 price target.
Stephens & Co. analyst Sudan Loganathan reiterates C4 Therapeutics (NASDAQ:CCCC) with a Overweight and maintains $6 price target.